Log in

Relevant bibliographies by topics / Seiwert / Journal articles

To see the other types of publications on this topic, follow the link: Seiwert.

Journal articles on the topic 'Seiwert'

Author: Grafiati

Published: 4 June 2021

Last updated: 13 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 20 journal articles for your research on the topic 'Seiwert.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Mettin, Martin. "Elvira Seiwert: Enthüllungen." Zeitschrift für philosophische Literatur 6, no. 1 (2018): 20–28. http://dx.doi.org/10.21827/zfphl.6.1.35416.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Hexham, Irving, and Karla Poewe. "Source Criticism and the Reconstruction of Reality A Reply to Brigitte Schoen and Hubert Seiwert." Nova Religio 6, no. 1 (2002): 129–36. http://dx.doi.org/10.1525/nr.2002.6.1.129.

Full text

Abstract:

This paper responds to criticism of our earlier work on the German anticult debate by Ms. Schoen and Prof. Dr. Seiwert. In it we argue that Schoen misunderstood and misread our article as a result of her obsession with published texts. Both Schoen and Seiwert underestimate the importance of history in creating the ethos that shapes the German debate about new religions.

APA, Harvard, Vancouver, ISO, and other styles

3

Hake, Sabine. "Proletarian Modernism and the Politics of Emotion: On Franz Wilhelm Seiwert and John Heartfield." Modernism/modernity 27, no. 4 (2020): 735–67. http://dx.doi.org/10.1353/mod.2020.0061.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Son, Min Young, Sung Eun Kim, Moo In Park, et al. "Tu1319 – Predictive Factors of Lymph Node Metastasis in Early Gastric Cancer Patients with Seiwert Type Ii/Iii." Gastroenterology 156, no. 6 (2019): S—1025. http://dx.doi.org/10.1016/s0016-5085(19)39516-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Tokunaga, Masanori, Eigo Akimoto, Reo Sato, Akio Kaito, and Takahiro Kinoshita. "Surgical outcomes of laparoscopic transhiatal lower mediastinal lymphadenectomy for seiwert type II adenocarcinoma of the esophagogastric junction." Journal of Clinical Oncology 37, no. 4_suppl (2019): 155. http://dx.doi.org/10.1200/jco.2019.37.4_suppl.155.

Full text

Abstract:

155 Background: Optimal surgical approach for Siewert type II adenocarcinoma of the esophagogastric junction (AEG-II) has not yet been determined, presumably due to complex anatomical structures and the limited number of reports regarding this aspect. The transhiatal approach is preferred in East Asia in cases with 30 mm or less esophageal invasion, and laparoscopic surgery is increasingly performed. However, the feasibility of the laparoscopic transhiatal approach for AEG-II is still unclear, and thus was investigated in this study. Methods: A total of 51 consecutive patients who underwent to

APA, Harvard, Vancouver, ISO, and other styles

6

Corell, R. A., L. K. Read, G. R. Riley, et al. "Complexes from Trypanosoma brucei that exhibit deletion editing and other editing-associated properties." Molecular and Cellular Biology 16, no. 4 (1996): 1410–18. http://dx.doi.org/10.1128/mcb.16.4.1410.

Full text

Abstract:

Transcripts from many mitochondrial genes in kinetoplastids undergo RNA editing, a posttranscriptional process which inserts and deletes uridines. By assaying for deletion editing in vitro, we found that the editing activity from Trypanosoma brucei mitochondrial lysates (S.D. Seiwert and K.D. Stuart), Science 266:114-117,1994) sediments with a peak of approximately 20S. RNA helicase, terminal uridylyl transferase, RNA ligase, and adenylation activities, which may have a role in editing, cosediment in a broad distribution, with most of each activity at 35 to 40S. Most ATPase 6 (A6) guide RNA an

APA, Harvard, Vancouver, ISO, and other styles

7

Ownby, David. "Popular Religious Movements and Heterodox Sects in Chinese History. By Seiwert Hubert. Leiden and Boston: Brill, 2003. xvi, 548 pp. $118.00 (cloth)." Journal of Asian Studies 63, no. 4 (2004): 1110–13. http://dx.doi.org/10.1017/s0021911804002645.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Choong, N. W., D. J. Haraf, E. E. Cohen, et al. "Randomized phase II study of concomitant chemoradiotherapy with 5-fluorouracil-hydroxyurea (FHX) compared to FHX and bevazicumab (BFHX) in intermediate stage head and neck cancer (HNC)." Journal of Clinical Oncology 25, no. 18_suppl (2007): 6034. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.6034.

Full text

Abstract:

6034 Background: Preclinical data supports inhibition of vascular endothelial growth factor (VEGF) to improve tumor radiosensitivity. Phase I data demonstates that BFHX was tolerable in HNC (Seiwert, pASCO2006). Here we present preliminary toxicity data from a randomized phase II trial in pts with PS 0–2, stage II-IV (T2–4 N0–1 M0) HNC. Methods: Pts were randomized (2:1) to receive either BFHX or FHX. Planned sample size is 72pts. Chemotherapy consists of 5- FU (600 mg/m2/day continuous infusion for 120 hrs), hydroxyurea (500 mg PO q12 hours for 11 doses) with or without bevacizumab (10 mg/kg

APA, Harvard, Vancouver, ISO, and other styles

9

Seiwert, Tanguy Y., Riyue Bao, Y.-H. Carol Tan, et al. "Correlation of constitutive PD-1 resistance in HNC with GM-CSF expression and presence of myeloid derived suppressor cells (MDSCs)." Journal of Clinical Oncology 35, no. 15_suppl (2017): 6049. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.6049.

Full text

Abstract:

6049 Background: PD-1 checkpoint blockade is active in head and neck squamous cell carcinomas (HNC) with a response rate of ~18% and significant impact on survival. However, only a subset of patients benefits (Seiwert, Lancet Oncol). Biomarkers such as PD-L1 IHC and the Interferon-Gamma gene expression profile (INF-G GEP) identify inflamed tumors with a higher chance of response (~35-40%). However, it remains unclear why the majority of INF-G inflamed tumors still do not respond, or how to overcome constitutive resistance. Methods: 50 anti-PD-1 treated recurrent/metastatic HNC patients were in

APA, Harvard, Vancouver, ISO, and other styles

10

Mückl, Stefan. "Besier, Gerhard, Seiwert, Hubert (Hg.), Die Religionsfreiheit und das Staat-Kirche-Verhältnis in Europa und den USA, Berlin: LIT Verlag 2013, 165 S. (= Religion - Staat - Gesellschaft. Zeitschrift für Glaubensformen und Weltanschauungen 14/1)." Archiv für katholisches Kirchenrecht 182, no. 2 (2013): 664–67. http://dx.doi.org/10.30965/2589045x-18202039.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Machiels, Jean-Pascal H., Lisa F. Licitra, Robert I. Haddad, et al. "LUX-H&N 1: A phase III, randomized trial of afatinib versus methotrexate (MTX) in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy." Journal of Clinical Oncology 30, no. 15_suppl (2012): TPS5598. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps5598.

Full text

Abstract:

TPS5598 Background: EGFR (ErbB1) is expressed in 90% of HNSCC and associated with poor prognosis. Despite clinical benefit (CB) of EGFR-targeted treatments such as cetuximab treatment resistance will occur resulting in a need for novel targeted treatments to improve prognosis. Afatinib is an ErbB Family Blocker that irreversibly blocks signaling from all relevant ErbB Family dimers and may overcome limitations of current EGFR-targeted treatments in HNSCC. In a randomized, proof-of-concept, Phase II trial, afatinib demonstrated comparable anti-tumor activity to cetuximab in pts with R/M HNSCC p

APA, Harvard, Vancouver, ISO, and other styles

12

Cupissol, Didier, Tanguy Y. Seiwert, Jérôme Fayette, et al. "A randomized, open-label, phase II study of afatinib versus cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Analysis of stage 2 (S2) following crossover." Journal of Clinical Oncology 31, no. 15_suppl (2013): 6001. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.6001.

Full text

Abstract:

6001 Background: This open-label trial assessed the efficacy of the irreversible ErbB Family Blocker afatinib (A) vs cetuximab (C) in R/M HNSCC pts following failure of platinum-containing therapy. In Stage 1 (S1), A and C had confirmed objective response rates (RECIST 1.0) of 16.1% vs 6.5% by investigator review (8.1% vs 9.7% independent central review [ICR]; Seiwert TY, et al. MHNCS 2012. Abs 235). S2 data after crossover are presented. Methods: In S1, pts were randomized 1:1 to oral A 50 mg/day or IV C 250 mg/m2/wk (400 mg/m2 IV loading dose) until progressive disease (PD) or intolerable dr

APA, Harvard, Vancouver, ISO, and other styles

13

Maes, Eric. "Edith Franke, Christoph Kleine und Heinz Mürmel, Hg.: Devianz und Dynamik. Festschrift für Hubert Seiwert zum 65. Geburtstag. Critical Studies in Religion/ Religionswissenschaft (CSRRW), Band 8 (Göttingen: Vandenhoeck & Ruprecht, 2014), 263 S., ISBN 978-3-525-54037-4, € 100,00." Zeitschrift für Religionswissenschaft 27, no. 2 (2019): 321–23. http://dx.doi.org/10.1515/zfr-2019-0028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Song, Alexander, Ron Ng, John Heller, et al. "251 Factors evaluated as predictors of exceptional response to PD-1 inhibitors in patients with head and neck squamous cell cancer." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (2020): A272. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0251.

Full text

Abstract:

BackgroundImmunotherapy has recently emerged as an alternative to traditional chemotherapy in the management of recurrent or metastatic head and neck squamous cell cancer (HNSCC). PD-1 inhibitors were approved for HNSCC in 2016 with ORR of 13–18% and CR of 4%.1, 2 Current research focuses on identifying predictors of response for better patient selection. We present HNSCC patients with exceptional response to PD-1 inhibitors in an attempt to highlight biomarkers that correlated with their remarkable response.MethodsWe analyzed all cases of HNSCC treated with single agent PD-1 inhibitors in the

APA, Harvard, Vancouver, ISO, and other styles

15

Bauman, Julie, Howard Burris, Jeffrey Clarke, et al. "798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (2020): A846. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0798.

Full text

Abstract:

BackgroundT-cell targeting of mutation-derived epitopes (neoantigens) has shown to drive anti-tumor responses. Immunizing patients against such neoantigens in combination with a checkpoint inhibitor (CPI) may elicit greater anti-tumor responses than CPI alone. Mutations are rarely shared between patients, thus requiring a personalized approach to vaccine design. mRNA-4157 is a lipid encapsulated mRNA based personalized cancer vaccine encoding neoantigens selected using a proprietary algorithm to induce neoantigen specific T cells and associated anti-tumor responses. This report includes update

APA, Harvard, Vancouver, ISO, and other styles

16

Gardiner, Mark Q., and Steven Engler. "Allies in the Fullness of Theory." Zeitschrift für Religionswissenschaft, September 13, 2021. http://dx.doi.org/10.1515/zfr-2021-0015.

Full text

Abstract:

Abstract In a recent article, Hubert Seiwert (2020) presents an approach to the study of religion that we develop (Engler and Gardiner, 2010) as an example of “empty theory”, and recommends how it can be salvaged. We clarify three things about our position: Seiwert misunderstands it at crucial points; it already includes his recommended rehabilitation; and it avoids postulating problematic and contentious ontological items, a potential problem that Seiwert’s own position has not addressed sufficiently.

APA, Harvard, Vancouver, ISO, and other styles

17

Schmidt-Leukel, Perry. "Religion: Historical Fact or Interpretive Theory? A Response to Hubert Seiwert." Zeitschrift für Religionswissenschaft, September 13, 2021. http://dx.doi.org/10.1515/zfr-2021-0012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Jahn, Sarah J. "Nun sag, wie hältst du’s mit der ‚Öffentlichkeit‘?" Zeitschrift für Religionswissenschaft 25, no. 1 (2017). http://dx.doi.org/10.1515/zfr-2016-0029.

Full text

Abstract:

ZusammenfassungDer Beitrag befasst sich mit Überlegungen zur Positionsbestimmung von Religionswissenschaft in der Öffentlichkeit. Ausgehend von Rudolphs Auseinandersetzung über die ideologiekritische Funktion von Religionswissenschaft (1978) wird anhand der Positionen von Tworuschka (2008, 2015), McCutcheon (2001), Wilke (2005), Seiwert (1998) und Klinkhammer (2001) deutlich, dass die aktuelle Gretchenfrage nicht neu ist, es im Gegenteil schon konkrete, aber auch divergente Aussagen über die Rolle von Religionswissenschaft in der Öffentlichkeit gibt. Dem Verständnis einer historisch-kritisch a

APA, Harvard, Vancouver, ISO, and other styles

19

"Wenn Du es eilig hast, gehe langsam. Das neue Zeitmanagement in einer beschleunigten Zeit (L. J. Seiwert)." Beton- und Stahlbetonbau 94, no. 5 (1999): 236. http://dx.doi.org/10.1002/best.199900830.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

"Erratum for the Research Article “Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy” by R. Cristescu, R. Mogg, M. Ayers, A. Albright, E. Murphy, J. Yearley, X. Sher, X. Q. Liu, H. Lu, M. Nebozhyn, C. Zhang, J. K. Lunceford, A. Joe, J. Cheng, A. L. Webber, N. Ibrahim, E. R. Plimack, P. A. Ott, T. Y. Seiwert, A. Ribas, T. K. McClanahan, J. E. Tomassini, A. Loboda, D. Kaufman." Science 363, no. 6430 (2019): eaax1384. http://dx.doi.org/10.1126/science.aax1384.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!